Related Party [Axis] Surface Ophthalmics [Member] Melt Pharmaceuticals [Member] Product and Service [Axis] Product Sales, Net [Member] Other Revenues [Member] Eton Pharmaceuticals [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Parent [Member] Noncontrolling Interest [Member] Ownership [Axis] Mayfield Pharmaceuticals, Inc. [Member] Stowe Pharmaceuticals, Inc. [Member] Legal Entity [Axis] TGV [Member] Antidilutive Securities [Axis] Warrant [Member] Stock Options [Member] Eton Pharmaceuticals, Inc. [Member] Melt Pharmaceuticals, Inc. [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Surface Pharmaceuticals Inc [Member] Commissions [Member] License [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Management Services Agreement [Member] Asset Purchase and License Agreement [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Title of Individual [Axis] Dr. Lindstrom [Member] Long Lived Assets Held-for-sale by Asset Type [Axis] Park Restructuring [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Licenses [Member] Trademarks [Member] Customer Relationships [Member] Trade Names [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Term Loan and Security Agreement [Member] SWK Funding LLC [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Base Rate [Member] SWK Amendment [Member] Business Loan Agreement [Member] Debt Instrument [Axis] Notes Payable [Member] Geographical [Axis] San Diego [Member] Ledgewood [Member] Lease Contractual Term [Axis] Additional Square Footage of Lease [Member] Nashville [Member] Irvine [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Common Stock One [Member] Director [Member] Plan Name [Axis] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Stock Option Plan [Member] Employees and Consultant [Member] Baum Performance Option [Member] Options Granted to Employees [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Board of Directors [Member] Restricted Stock Units [Member] New Member of Board of Directors [Member] New Member of Board of Directors One [Member] Unvested RSUs [Member] Class of Warrant or Right [Axis] Lender Warrants [Member] Settlement Warrants [Member] Lender Warrants One [Member] Elle Pharmaceutical, LLC [Member] Restricted Stock [Member] Consultants [Member] Employees [Member] Income Statement Location [Axis] Selling, General and Administrative [Member] Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Scenario [Axis] Initial Payment [Member] License Agreement [Member] DirectorSellingAndAdminstrativeMember Final Payment [Member] Injectable Asset Purchase Agreement [Member] Dexycu Agreement [Member] Sales and Marketing Agreements [Member] Asset Purchase, License and Related Agreements [Member] Consolidation Items [Axis] Operating Segments [Member] Segments [Axis] Pharmaceutical Compounding [Member] Pharmaceutical Drug Development [Member] Corporate, Non-Segment [Member] Research and Development Expense [Member] Concentration Risk Type [Axis] Three Main Suppliers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items] ASSETS Current assets Cash and cash equivalents, including restricted cash of $200 Investment in Eton Pharmaceuticals Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Operating lease right-of-use assets Intangible assets, net Investments Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits Current portion of paycheck protection program loan payable Current portion of loan payable, net of unamortized debt discount Current portion of operating lease liabilities Current portion of finance lease obligations Total current liabilities Operating lease liabilities, net of current portion Finance lease obligations, net of current portion Accrued expenses, net of current portion Paycheck protection program loan payable, net of current portion Loan payable, net of current portion and unamortized debt discount TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Common stock, $0.001 par value, 50,000,000 shares authorized, 25,652,169 and 25,526,931 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Additional paid-in capital Accumulated deficit TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY Noncontrolling interests TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND EQUITY Statement of Financial Position [Abstract] Restricted cash Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Revenues: Total revenues Cost of sales Gross profit Operating expenses: Selling, general and administrative Research and development Impairment of long-lived assets Total operating expenses Income (loss) from operations Other income (expense): Interest expense, net Investment (loss) gain, net Other income, net Total other income (expense), net Income (loss) before income taxes Income tax benefit, net Total net income (loss) including noncontrolling interests Net loss attributable to noncontrolling interests Net income (loss) attributable to Harrow Health, Inc. Basic net income (loss) per share of common stock Diluted net income (loss) per share of common stock Weighted average number of shares of common stock outstanding, basic Weighted average number of shares of common stock outstanding, diluted Beginning balance, value Balance, shares Exercise of warrants Exercise of warrants, shares Exercise of employee stock-based options, net of tax withholding Exercise of employee stock-based options, net of tax withholding , shares Stock-based payment for services provided Stock-based payment for services provided, shares Stock-based compensation expense Vesting of RSUs Vesting of RSUs, shares Net loss Ending balance, value Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss (including noncontrolling interests) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization of property, plant and equipment Amortization of intangible assets Amortization of operating lease right-of-use assets Amortization of debt issuance costs and discount Provision for bad debt expense Investment gain from Eton, net Investment loss from Surface, net Investment loss (gain) from Melt, net Loss on sale and disposal of equipment Interest paid-in-kind on loan payable Impairment of long-lived assets Stock-based payment of consulting services Stock-based compensation Changes in assets and liabilities: Accounts receivable, net of provision for bad debt expense Inventories Prepaid expenses and other current assets Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Proceeds on sale and disposal of assets Investment in patent and trademark assets Purchases of property, plant and equipment NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Payments on finance lease obligations Proceeds from SWK debt Principal payments on loan payable Payments of costs related to amendment of note payable Net proceeds from Payroll Protection Program loan payable Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU and options NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash and cash equivalents Restricted cash CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for income taxes Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: New and revaluation of right-of-use asset obtained in exchange for lease obligation Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUES Investments, Debt and Equity Securities [Abstract] INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS Inventory Disclosure [Abstract] INVENTORIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] DEBT Leases [Abstract] LEASES Equity [Abstract] STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] SEGMENT INFORMATION AND CONCENTRATIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Segments Noncontrolling Interests Basic and Diluted Net Income (Loss) per Common Share Investment in Eton Pharmaceuticals, Inc. – Related Party Investment in Melt Pharmaceuticals, Inc. – Related Party Investment in Surface Ophthalmics, Inc. – Related Party Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements SCHEDULE OF BASIC EARNINGS PER COMMON SHARE SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE SCHEDULE OF DISAGGREGATED REVENUE SCHEDULE OF CONDENSED INCOME STATEMENT SCHEDULE OF CONDENSED BALANCE SHEET SUMMARY OF CONDENSED INCOME STATEMENT SUMMARY OF CONDENSED BALANCE SHEET SCHEDULE OF INVENTORIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SUMMARY OF FUTURE MINIMUM PAYMENTS SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE SCHEDULE OF STOCK OPTION PLAN ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION Business Acquisition [Line Items] Equity method investment, ownership percentage Consolidation basis, description Operating income (loss) Accumulated deficit Net cash provided by (used in) operating activities Cash, cash equivalents, restricted cash and restricted cash equivalents Numerator – net income (loss) attributable to Harrow Health, Inc. Denominator – weighted average number of shares outstanding, basic Net income (loss) per share, basic Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Dilutive common equivalent shares Numerator – net income (loss) attributable to Harrow Health, Inc. Dilutive common equivalent shares Number of shares used for diluted earnings per share computation Net income (loss) per share, diluted Entity Listings [Line Items] Non-controlling interest description Unvested restricted stock units Vested restricted stock units Number of shares owned Shares issued, price per share Gain (loss) on investments Investment owned, at fair value Proceeds from issuance of preferred stock and preference stock Gain on deconsolidation amount Unrealized gain (loss) on investments Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Total Revenues Revenues, net Loss from operations Net loss Current assets Non current assets Total assets Total liabilities Total preferred stock and stockholders' equity Total liabilities and stockholders' equity Royalty payment percentage on net sales Administrative expenses Reimbursable expenses due Total stockholders equity Raw materials Work in progress Finished goods Total inventories Prepaid insurance Other prepaid expenses Receivable due from related party Deposits and other current assets Total prepaid expenses and other current assets Computer software and hardware Furniture and equipment Lab and pharmacy equipment Leasehold improvements  Property, plant and equipment, gross Accumulated depreciation and amortization Property, plant and equipment, net  Schedule of Long Lived Assets Held-for-sale [Table] Long Lived Assets Held-for-sale [Line Items] Depreciation, amortization and accretion, net Impairment of property, plant and equipment Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Amortization periods (in years) Cost Accumulated amortization Impairment Net Carrying value Amortization periods description Amortization of intangible assets Remainder of 2020 2021 2022 2023 2024 Thereafter Intangible assets Impairment of intangible assets Changes in carrying value goodwill Accounts payable Other accrued expenses Accrued interest Accrued exit fee for note payable Total accounts payable and accrued expenses Less: Current portion Non-current total accrued expenses Remainder of 2020 2021 2022 2023 Total minimum payments Less: amount representing estimated interest Loans payable, gross Less: unamortized discount Notes payable Less: current portion, net of unamortized discount Loans payable, net of current portion and unamortized debt discount Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt principal amount Debt instrument interest rate description Debt instrument interest rate Amortization of debt discount Remainder of 2020 2021 2022 2023 2024 Thereafter Total minimum lease payments Less: amount representing interest payments Total operating lease liabilities Less: current portion, operating lease liabilities Operating lease liabilities, net of current portion Remainder of 2020 2021 2022 2023 2024 Total minimum lease payments Less: amount representing interest payments Present value of future minimum lease payments Less: current portion, finance lease obligation Finance lease obligation, net of current portion Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Operating lease space Operating lease expires date Lease term description Other income (expense) Weighted average incremental borrowing rate, operating lease Weighted average remaining lease term, operating lease Cash paid in operating lease liability Operating lease expense Weighted average incremental borrowing rate, finance lease Weighted average remaining lease term, finance lease Operating leases, income statement, depreciation expense on property subject to or held-for-lease Finance Lease, Interest Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares, Outstanding, Beginning balance Weighted Avg. Exercise Price, Outstanding, Beginning balance Number of shares, Options granted Weighted Avg. Exercise Price, Options granted Number of shares, Options exercised Weighted Avg. Exercise Price, Options exercised Number of shares, Options cancelled/forfeited Weighted Avg. Exercise Price, Options cancelled/forfeited Number of shares, Outstanding, Ending balance Weighted Avg. Exercise Price, Outstanding, Ending balance Weighted Avg. Remaining Contractual Life, Options outstanding Aggregate Intrinsic Value, Options outstanding Number of shares, Options exercisable Weighted Avg. Exercise Price, Exercisable Ending Balance Weighted Avg. Remaining Contractual Life, Options exercisable Aggregate Intrinsic Value, Options exercisable Number of shares, Options vested and expected to vest Weighted Avg. Exercise Price, Vested and expected to vest Weighted Avg. Remaining Contractual Life, Options vested and expected to vest Aggregate Intrinsic Value, Options vested and expected to vest Weighted-average fair value of options granted Expected terms (in years) Expected volatility, minimum Expected volatility, maximum Risk-free interest rate, minimum Risk-free interest rate, maximum Dividend yield Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, minimum Range of Exercise Prices, maximum Number of Options Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercisable Exercise Price Number of RSUs unvested, Outstanding, Beginning balance Weighted Average Grant Date Fair Value, Beginning balance Number of RSUs granted Weighted Average Grant Date Fair Value, RSUs granted Number of RSUs vested Weighted Average Grant Date Fair Value, RSUs vested Number of RSUs cancelled/forfeited Number of RSUs unvested, Outstanding, Ending balance Weighted Average Grant Date Fair Value, Ending balance Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Number of Shares Warrants Outstanding, beginning balance Weighted Avg. Exercise Price, Outstanding, beginning balance Number of Shares Warrants Outstanding, Granted Number of Shares Warrants Outstanding, Exercised Number of Shares Warrants Outstanding, Expired Number of Shares Warrants Outstanding and Exercisable, ending balance Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance Weighted average remaining contractual life of the outstanding warrants in years Issue Date Warrants Outstanding Exercise Price Expiration Date Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Stock based compensation related to equity instruments granted to related parties Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Shares issued of restricted common stock, shares Fair value of restricted common stock issued Number of common stock issued on cashless exercise Number of shares, options granted Exercise price of options Common stock withheld for payroll tax withholdings, shares Common stock withheld for payroll tax withholdings, value Restricted stock units vested Maximum number of common stock issuance under the plan Shares available for future issuances Closing price of common stock price per share Weighted avg. remaining contractual life, options exercisable Share-based compensation arrangement by share-based payment award, plan modification, description and terms Average stock price Weighted avg. remaining contractual life, options outstanding Share-based compensation arrangement by share-based payment award, options, vested in period, fair value Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate Forfeiture factor, percentage Unrecognized compensation expense related to unvested stock options granted under the plan Expense expected to recognize over the weighted-average remaining vesting period Stock issued during period, shares, acquisitions Aggregate purchase price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Royalty payment description Royalty Expense Sales revenue net Milestone payment in cash Agreement expiration, description Sales commissions and fees Accounts Payable Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Gross profit Segment contribution Operating income (loss) Amortization Asset sales and impairments, net Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Number of operating segments, description Percentage of sales derived from large number of customer Subsequent Event [Table] Subsequent Event [Line Items] Stock issued during period, shares, new issues Surface Pharmaceuticals [Member] Melt Pharmaceuticals [Member] Product Sales, Net [Member] Eton Pharmaceuticals [Member] Stock issued during period for exercise of warrants. Stock issued during period shares for exercise of warrants. Mayfield Pharmaceuticals, Inc. [Member] Stowe Pharmaceuticals, Inc. [Member] TGV-Health, LLC [Member] Consolidation basis, description. The cumulative amount of the reporting entity's undistributed earnings or deficit. Noncontrolling Interests [Policy Text Block] Disclosure of accounting policy for investment in financial asset. Disclosure of accounting policy for investment in financial asset. Recently Adopted Accounting Pronouncements [Policy Text Block] The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Amortization of operating lease right-of-use assets. Investment loss (gain) from Eton, net. Investment loss (gain) from Surface, net. Investment loss (gain) from Melt, net. Payments of Costs Related to Amendment of Loan Payable. Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU and options. RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH ABSTRACT. Reconciliation of Cash and cash equivalents. Reconciliation Restricted cash. Cash and cash equivalents and Restricted cash at end of period. New and revaluation of right-of-use asset obtained in exchange for lease obligation. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Stock Options [Member] Incremental Common Shares Attributable to Dilutive common equivalents. Commissions [Member] Investments and Agreements Related Party Transactions [Text Block] Schedule of Condensed Balance Sheet [Table Text Block] Schedule of Condensed Balance Sheet [Table Text Block] Royalty payment percentage on net sales. Melt Pharmaceuticals, Inc. [Member] Asset Purchase Agreement [Member] Management Services Agreement [Member] Surface Pharmaceuticals Inc [Member] Asset Purchase and License Agreement [Member] Dr. Lindstrom [Member] Schedule of Prepaid Expenses and Other Current Assets [Table Text Block] Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Finite Lived Intangible Assets Impairment. Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Licenses [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Term Loan and Security Agreement [Member] SWK Funding LLC [Member] SWK Amendment [Member] Business Loan Agreement [Member] Notes Payable [Member] Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Finance lease liabilities current. San Diego [Member] Lease expiration date description. Ledgewood [Member] Additional Square Footage of Lease [Member] Nashville [Member] Irvine [Member] Weighted average incremental borrowing rate, operating lease. Cash paid in operating lease liability. Weighted average incremental borrowing rate, finance lease. Schedule Of Warrants Outstanding and Exercisable [Table Text Block] Stock Option Plan [Member] Options Granted to Employees [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price. Number of shares warrants outstanding and exercisable, ending balance. Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term. Warrants issuance date. Lender Warrants [Member] Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format. Settlement Warrants [Member] Lender Warrants One [Member] Employees [Member] Selling, General and Administrative [Member] Consultants [Member] Number of common stock issued on cashless exercise. Common stock withheld for payroll tax withholdings, value. Common Stock One [Member] Restricted stock units vested. 2017 Incentive Stock and Awards Plan [Member] Closing price of common stock price per share. Stock Option Plan [Member] Employees and Consultant [Member] Baum Performance Option [Member] Average stock price. Forfeiture factor, percentage. Board of Directors [Member] Restricted Stock Units [Member] New Member of Board of Directors [Member] New Member of Board of Directors One [Member] Unvested RSUs [Member] Elle Pharmaceutical, LLC [Member] Aggregate purchase price. Royalty payment description. Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Initial Payment [Member] License Agreement [Member] Second Payment [Member] Final Payment [Member] Net sales of product. Milestone payment in cash. Injectable Asset Purchase Agreement [Member] Agreeement expiration description. Dexycu Agreement [Member] Sales and Marketing Agreements [Member] Asset Purchase, License and Related Agreements [Member] Number of operating segments, description. Three Main Suppliers [Member] Pharmaceutical Compounding [Member] Pharmaceutical Drug Development [Member] Segment contribution. Impairment and disposal of long-lived assets. Operating lease liabilities, net of current portion. Impairment of long-lived assets. Other Revenues [Member] Unvested restricted stock units. Vested restricted stock units. Number of shares owned. Eton Pharmaceuticals, Inc. [Member] Park Restructuring [Member] Common stock withheld for payroll tax withholdings, shares Stock Option Plan [Member] [Default Label] Assets, Current Liabilities, Current Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cost of Goods and Services Sold Operating Expenses Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Shares, Outstanding Stock Issued During Period, Value, Employee Benefit Plan Investment gain from Eton, net Investment loss from Surface, net Investment loss (gain) from Melt, net Gain (Loss) on Disposition of Assets Impairment of long-lived assets [Default Label] Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Notes Payable Payments of costs related to amendment of note payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Restricted cash [Default Label] CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD Commitments and Contingencies Disclosure [Text Block] Accumulated deficit [Default Label] Dilutive common equivalent shares [Default Label] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amortization of Intangible Assets Finite-Lived Intangible Assets, Net Accounts Payable and Accrued Liabilities Long-Term Debt, Maturity, Remainder of Fiscal Year Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-term Debt Interest Payable, Current Debt Instrument, Unamortized Discount Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating lease liabilities, net of current portion [Default Label] Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, to be Paid, Year Four Finance Lease, Liability, Payment, Due Finance Lease, Liability, Undiscounted Excess Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted Avg. Exercise Price, Outstanding, beginning balance Number of Shares Warrants Outstanding and Exercisable, ending balance Warrant